Results 111 to 120 of about 51,116 (225)
Congestion, decongestion, renal function and diuretics in (ESC) heart failure
ESC Heart Failure, Volume 12, Issue 2, Page 730-732, April 2025.
Jan Biegus +2 more
wiley +1 more source
Clinical Case Reports, Volume 14, Issue 4, April 2026.Echocardiographic findings in dilated cardiomyopathy secondary to untreated acromegaly. (A) Apical four‐chamber view showing biventricular and biatrial dilation. (B‐C) Colour Doppler demonstrating mitral, aortic, and tricuspid regurgitation. (D) Reduced global longitudinal strain (GLS: −6.5%), consistent with severe systolic dysfunction.
Cristian Orlando Porras Bueno +4 more
wiley +1 more source
Clinical Case Reports, Volume 14, Issue 4, April 2026.ABSTRACT Lateral medullary syndrome (LMS) or Wallenberg's syndrome is usually caused by a cerebrovascular accident of the vertebral artery or the posterior inferior cerebellar artery (PICA), leading to damage to the dorsolateral aspects of the medulla oblongata.
Abera Kuma +5 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 891-904, April 2026.Limited evidence exists synthesizing the risk of acute kidney injury (AKI) associated with the concomitant administration of multiple nephrotoxic drugs, and even less examining the concept of nephrotoxic burden. The objective of this scoping review was to (1) identify definitions of nephrotoxic burden; (2) methods used to quantify (use of calculations)
Wafa Alatawi +6 more
wiley +1 more source
Olmesartan‐induced gastritis with no lower gastrointestinal symptoms: A case report
DEN Open, Volume 6, Issue 1, April 2026.Abstract A 74‐year‐old man with decreased appetite, weight, and heartburn was referred to our hospital. His medications included olmesartan. Esophagogastroduodenoscopy (EGD) revealed antral‐dominant erosive gastritis and nodular mucosa. A gastric biopsy revealed inflammatory cell infiltration.
Satoshi Kosaka +2 more
wiley +1 more source
The Kaohsiung Journal of Medical Sciences, Volume 42, Issue 4, April 2026.ABSTRACT Sacubitril/valsartan (Sac/Val) has emerged as an effective compound with myocardium‐protective functions in experimental and clinical trials for heart failure. This study investigated the function of Sac/Val in hypertensive heart disease (HHD) and explored the underlying mechanism.
Yan‐Jun Yang, Jiu‐Sheng Li
wiley +1 more source
Antihypertensive medications and risk of Alzheimer's disease: Evidence for specific medication use
Alzheimer's &Dementia: Translational Research &Clinical Interventions, Volume 12, Issue 2, April/June 2026.Abstract BACKGROUND Hypertension is a modifiable risk factor for Alzheimer's disease (AD). Specific antihypertensive classes may lower/increase AD risk by affecting the renin–angiotensin–aldosterone system. METHODS We investigated AD risk in relation to antihypertensive medications in a population‐based study of 33,714 incident AD cases and 897,872 ...
Osvaldo J. Laurido‐Soto +6 more
wiley +1 more source
British Journal of Pharmacology, Volume 183, Issue 7, Page 1502-1516, April 2026.Background and Purpose Novel heart failure (HF) pharmacotherapies, including angiotensin receptor‐neprilysin inhibitor (ARNI) and sodium‐glucose cotransporter 2 inhibitors (SGLT2is), may confer cardiovascular benefits by attenuating myocardial fibrosis. However, direct evidence from human failing myocardial samples is limited.
Dávid Nagy +10 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2953-2961, April 2026.Abstract Objective People with chronic kidney disease (CKD) and diabetes are at high risk of cardiovascular disease (CVD). Aortic pulse wave velocity (Ao‐PWV) is an independent predictor of CVD. Cardiovascular outcome trials (CVOTs) with glucagon like peptide‐1 receptor agonist (GLP‐1 RA) class demonstrate notable differences, with lixisenatide having ...
Nikolaos Fountoulakis +8 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3137-3145, April 2026.Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting adiposity is central to HFpEF pathogenesis. We conducted an updated network meta‐analysis to compare the efficacy of emerging and established HFpEF therapies ...
Szu‐Han Chen +7 more
wiley +1 more source